APO Research
Talk to an analyst

APO RESEARCH · REPORT

AI In Drug Development

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global AI In Drug Development Market Outlook and Growth Opportunities 2026

15 April 2026Not stated

Choose your research edition.

Industry ResearchAI In Drug Development Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal AI In Drug Development Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal AI In Drug Development Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal AI In Drug Development Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal AI In Drug Development Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global AI In Drug Development market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for AI In Drug Development is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the AI In Drug Development market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the AI In Drug Development market include Pfizer, AstraZeneca, Johnson & Johnson, Novartis, Sanofi, Roche, Insilico Medicine, Exscientia and BenevolentAI, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global AI In Drug Development market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of AI In Drug Development and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents AI In Drug Development revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global AI In Drug Development market.

AI In Drug Development Segment by Company

Pfizer

AstraZeneca

Johnson & Johnson

Novartis

Sanofi

Roche

Insilico Medicine

Exscientia

BenevolentAI

Recursion Pharmaceuticals

Atomwise

Isomorphic Labs

XtalPi

Deep Genomics

Relay Therapeutics

AI In Drug Development Segment by Type

Software

Services

AI In Drug Development Segment by Application

Biopharmaceuticals

Synthetic Pharmaceuticals

Others

AI In Drug Development Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global AI In Drug Development status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the AI In Drug Development key companies, revenue, market share, and recent developments.

3. To split the AI In Drug Development breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions AI In Drug Development market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify AI In Drug Development significant trends, drivers, influence factors in global and regions.

6. To analyze AI In Drug Development competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AI In Drug Development market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of AI In Drug Development and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AI In Drug Development.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global AI In Drug Development industry.

Chapter 3: Detailed analysis of AI In Drug Development company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of AI In Drug Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of AI In Drug Development in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. AI In Drug Development Industry Trends Table 2. AI In Drug Development Industry Drivers Table 3. AI In Drug Development Industry Opportunities and Challenges Table 4. AI In Drug Development Industry Restraints Table 5. Global AI In Drug Development Revenue by Company (US$ Million) & (2021-2026) Table 6. Global AI In Drug Development Revenue Share by Company (2021-2026) Table 7. Global AI In Drug Development Company Ranking, (2024-2026) & (US$ Million) Table 8. Global AI In Drug Development Key Company Manufacturing Base & Headquarters Table 9. Global AI In Drug Development Company, Product Type & Application Table 10. Global AI In Drug Development Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global AI In Drug Development by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Software Table 15. Significant Companies of Services Table 16. Global AI In Drug Development Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global AI In Drug Development Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global AI In Drug Development Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global AI In Drug Development Sales Value Share by Type (2021-2026) Table 20. Global AI In Drug Development Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Biopharmaceuticals Table 22. Significant Companies of Synthetic Pharmaceuticals Table 23. Significant Companies of Others Table 24. Global AI In Drug Development Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global AI In Drug Development Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global AI In Drug Development Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global AI In Drug Development Sales Value Share by Application (2021-2026) Table 28. Global AI In Drug Development Sales Value Share by Application (2027-2032) Table 29. Global AI In Drug Development Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global AI In Drug Development Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global AI In Drug Development Sales Value Share by Region (2021-2026) Table 32. Global AI In Drug Development Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global AI In Drug Development Sales Value Share by Region (2027-2032) Table 34. Global AI In Drug Development Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global AI In Drug Development Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global AI In Drug Development Sales Value Market Share by Country (2021-2026) Table 37. Global AI In Drug Development Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global AI In Drug Development Sales Value Market Share by Country (2027-2032) Table 39. Pfizer Company Information Table 40. Pfizer Business Overview Table 41. Pfizer AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Pfizer AI In Drug Development Product Portfolio Table 43. Pfizer Recent Development Table 44. AstraZeneca Company Information Table 45. AstraZeneca Business Overview Table 46. AstraZeneca AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. AstraZeneca AI In Drug Development Product Portfolio Table 48. AstraZeneca Recent Development Table 49. Johnson & Johnson Company Information Table 50. Johnson & Johnson Business Overview Table 51. Johnson & Johnson AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Johnson & Johnson AI In Drug Development Product Portfolio Table 53. Johnson & Johnson Recent Development Table 54. Novartis Company Information Table 55. Novartis Business Overview Table 56. Novartis AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Novartis AI In Drug Development Product Portfolio Table 58. Novartis Recent Development Table 59. Sanofi Company Information Table 60. Sanofi Business Overview Table 61. Sanofi AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Sanofi AI In Drug Development Product Portfolio Table 63. Sanofi Recent Development Table 64. Roche Company Information Table 65. Roche Business Overview Table 66. Roche AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Roche AI In Drug Development Product Portfolio Table 68. Roche Recent Development Table 69. Insilico Medicine Company Information Table 70. Insilico Medicine Business Overview Table 71. Insilico Medicine AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Insilico Medicine AI In Drug Development Product Portfolio Table 73. Insilico Medicine Recent Development Table 74. Exscientia Company Information Table 75. Exscientia Business Overview Table 76. Exscientia AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Exscientia AI In Drug Development Product Portfolio Table 78. Exscientia Recent Development Table 79. BenevolentAI Company Information Table 80. BenevolentAI Business Overview Table 81. BenevolentAI AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. BenevolentAI AI In Drug Development Product Portfolio Table 83. BenevolentAI Recent Development Table 84. Recursion Pharmaceuticals Company Information Table 85. Recursion Pharmaceuticals Business Overview Table 86. Recursion Pharmaceuticals AI In Drug Development Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Recursion Pharmaceuticals AI In Drug Development Product Portfolio Table 88. Recursion Pharmaceuticals Recent Development Table 89. Atomwise Company Information Table 90. Atomwise Business Overview Table 91. Atomwise AI In Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Atomwise AI In Drug Development Product Portfolio Table 93. Atomwise Recent Development Table 94. Isomorphic Labs Company Information Table 95. Isomorphic Labs Business Overview Table 96. Isomorphic Labs AI In Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Isomorphic Labs AI In Drug Development Product Portfolio Table 98. Isomorphic Labs Recent Development Table 99. XtalPi Company Information Table 100. XtalPi Business Overview Table 101. XtalPi AI In Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. XtalPi AI In Drug Development Product Portfolio Table 103. XtalPi Recent Development Table 104. Deep Genomics Company Information Table 105. Deep Genomics Business Overview Table 106. Deep Genomics AI In Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Deep Genomics AI In Drug Development Product Portfolio Table 108. Deep Genomics Recent Development Table 109. Relay Therapeutics Company Information Table 110. Relay Therapeutics Business Overview Table 111. Relay Therapeutics AI In Drug Development Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Relay Therapeutics AI In Drug Development Product Portfolio Table 113. Relay Therapeutics Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. AI In Drug Development Product Image Figure 2. Global AI In Drug Development Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global AI In Drug Development Market Size (2021-2032) & (US$ Million) Figure 4. Global AI In Drug Development Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Software Image Figure 8. Services Image Figure 9. Global AI In Drug Development Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global AI In Drug Development Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global AI In Drug Development Sales Value Share by Type (2021-2032) Figure 12. Biopharmaceuticals Image Figure 13. Synthetic Pharmaceuticals Image Figure 14. Others Image Figure 15. Global AI In Drug Development Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global AI In Drug Development Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global AI In Drug Development Sales Value Share by Application (2021-2032) Figure 18. Global AI In Drug Development Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global AI In Drug Development Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America AI In Drug Development Sales Value (2021-2032) & (US$ Million) Figure 21. North America AI In Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe AI In Drug Development Sales Value (2021-2032) & (US$ Million) Figure 23. Europe AI In Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific AI In Drug Development Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific AI In Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America AI In Drug Development Sales Value (2021-2032) & (US$ Million) Figure 27. South America AI In Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa AI In Drug Development Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa AI In Drug Development Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt AI In Drug Development Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt AI In Drug Development Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt AI In Drug Development Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Software
  • Services
Applications
  • Biopharmaceuticals
  • Synthetic Pharmaceuticals
  • Others
Companies covered
  • Pfizer
  • AstraZeneca
  • Johnson & Johnson
  • Novartis
  • Sanofi
  • Roche
  • Insilico Medicine
  • Exscientia
  • BenevolentAI
  • Recursion Pharmaceuticals
  • Atomwise
  • Isomorphic Labs
  • XtalPi
  • Deep Genomics
  • Relay Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global AI In Drug Development Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global AI In Drug Development Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 AI In Drug Development Market Dynamics
  1. 2.1 AI In Drug Development Industry Trends
  2. 2.2 AI In Drug Development Industry Drivers
  3. 2.3 AI In Drug Development Industry Opportunities and Challenges
  4. 2.4 AI In Drug Development Industry Restraints
3 AI In Drug Development Market by Company
  1. 3.1 Global AI In Drug Development Company Revenue Ranking in 2025
  2. 3.2 Global AI In Drug Development Revenue by Company (2021-2026)
  3. 3.3 Global AI In Drug Development Company Ranking (2024-2026)
  4. 3.4 Global AI In Drug Development Company Manufacturing Base and Headquarters
  5. 3.5 Global AI In Drug Development Company Product Type and Application
  6. 3.6 Global AI In Drug Development Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global AI In Drug Development Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 AI In Drug Development Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 AI In Drug Development Market by Type
  1. 4.1 AI In Drug Development Type Introduction
  2. 4.1.1 Software
  3. 4.1.2 Services
  4. 4.2 Global AI In Drug Development Sales Value by Type
  5. 4.2.1 Global AI In Drug Development Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global AI In Drug Development Sales Value by Type (2021-2032)
  7. 4.2.3 Global AI In Drug Development Sales Value Share by Type (2021-2032)
5 AI In Drug Development Market by Application
  1. 5.1 AI In Drug Development Application Introduction
  2. 5.1.1 Biopharmaceuticals
  3. 5.1.2 Synthetic Pharmaceuticals
  4. 5.1.3 Others
  5. 5.2 Global AI In Drug Development Sales Value by Application
  6. 5.2.1 Global AI In Drug Development Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global AI In Drug Development Sales Value by Application (2021-2032)
  8. 5.2.3 Global AI In Drug Development Sales Value Share by Application (2021-2032)
6 AI In Drug Development Regional Value Analysis
  1. 6.1 Global AI In Drug Development Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global AI In Drug Development Sales Value by Region (2021-2032)
  3. 6.2.1 Global AI In Drug Development Sales Value by Region: 2021-2026
  4. 6.2.2 Global AI In Drug Development Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America AI In Drug Development Sales Value (2021-2032)
  7. 6.3.2 North America AI In Drug Development Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe AI In Drug Development Sales Value (2021-2032)
  10. 6.4.2 Europe AI In Drug Development Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific AI In Drug Development Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific AI In Drug Development Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America AI In Drug Development Sales Value (2021-2032)
  16. 6.6.2 South America AI In Drug Development Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa AI In Drug Development Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa AI In Drug Development Sales Value Share by Country, 2025 VS 2032
7 AI In Drug Development Country-level Value Analysis
  1. 7.1 Global AI In Drug Development Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global AI In Drug Development Sales Value by Country (2021-2032)
  3. 7.2.1 Global AI In Drug Development Sales Value by Country (2021-2026)
  4. 7.2.2 Global AI In Drug Development Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA AI In Drug Development Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada AI In Drug Development Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico AI In Drug Development Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany AI In Drug Development Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France AI In Drug Development Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. AI In Drug Development Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy AI In Drug Development Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain AI In Drug Development Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia AI In Drug Development Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands AI In Drug Development Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries AI In Drug Development Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China AI In Drug Development Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan AI In Drug Development Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea AI In Drug Development Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India AI In Drug Development Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia AI In Drug Development Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia AI In Drug Development Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil AI In Drug Development Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina AI In Drug Development Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile AI In Drug Development Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia AI In Drug Development Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru AI In Drug Development Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia AI In Drug Development Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel AI In Drug Development Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE AI In Drug Development Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey AI In Drug Development Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran AI In Drug Development Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran AI In Drug Development Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt AI In Drug Development Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt AI In Drug Development Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt AI In Drug Development Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer AI In Drug Development Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer AI In Drug Development Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 AstraZeneca
  8. 8.2.1 AstraZeneca Company Information
  9. 8.2.2 AstraZeneca Business Overview
  10. 8.2.3 AstraZeneca AI In Drug Development Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AstraZeneca AI In Drug Development Product Portfolio
  12. 8.2.5 AstraZeneca Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson AI In Drug Development Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson AI In Drug Development Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis AI In Drug Development Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis AI In Drug Development Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi AI In Drug Development Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi AI In Drug Development Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche AI In Drug Development Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche AI In Drug Development Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Insilico Medicine
  38. 8.7.1 Insilico Medicine Company Information
  39. 8.7.2 Insilico Medicine Business Overview
  40. 8.7.3 Insilico Medicine AI In Drug Development Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Insilico Medicine AI In Drug Development Product Portfolio
  42. 8.7.5 Insilico Medicine Recent Developments
  43. 8.8 Exscientia
  44. 8.8.1 Exscientia Company Information
  45. 8.8.2 Exscientia Business Overview
  46. 8.8.3 Exscientia AI In Drug Development Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Exscientia AI In Drug Development Product Portfolio
  48. 8.8.5 Exscientia Recent Developments
  49. 8.9 BenevolentAI
  50. 8.9.1 BenevolentAI Company Information
  51. 8.9.2 BenevolentAI Business Overview
  52. 8.9.3 BenevolentAI AI In Drug Development Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BenevolentAI AI In Drug Development Product Portfolio
  54. 8.9.5 BenevolentAI Recent Developments
  55. 8.10 Recursion Pharmaceuticals
  56. 8.10.1 Recursion Pharmaceuticals Company Information
  57. 8.10.2 Recursion Pharmaceuticals Business Overview
  58. 8.10.3 Recursion Pharmaceuticals AI In Drug Development Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Recursion Pharmaceuticals AI In Drug Development Product Portfolio
  60. 8.10.5 Recursion Pharmaceuticals Recent Developments
  61. 8.11 Atomwise
  62. 8.11.1 Atomwise Company Information
  63. 8.11.2 Atomwise Business Overview
  64. 8.11.3 Atomwise AI In Drug Development Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Atomwise AI In Drug Development Product Portfolio
  66. 8.11.5 Atomwise Recent Developments
  67. 8.12 Isomorphic Labs
  68. 8.12.1 Isomorphic Labs Company Information
  69. 8.12.2 Isomorphic Labs Business Overview
  70. 8.12.3 Isomorphic Labs AI In Drug Development Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Isomorphic Labs AI In Drug Development Product Portfolio
  72. 8.12.5 Isomorphic Labs Recent Developments
  73. 8.13 XtalPi
  74. 8.13.1 XtalPi Company Information
  75. 8.13.2 XtalPi Business Overview
  76. 8.13.3 XtalPi AI In Drug Development Revenue and Gross Margin (2021-2026)
  77. 8.13.4 XtalPi AI In Drug Development Product Portfolio
  78. 8.13.5 XtalPi Recent Developments
  79. 8.14 Deep Genomics
  80. 8.14.1 Deep Genomics Company Information
  81. 8.14.2 Deep Genomics Business Overview
  82. 8.14.3 Deep Genomics AI In Drug Development Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Deep Genomics AI In Drug Development Product Portfolio
  84. 8.14.5 Deep Genomics Recent Developments
  85. 8.15 Relay Therapeutics
  86. 8.15.1 Relay Therapeutics Company Information
  87. 8.15.2 Relay Therapeutics Business Overview
  88. 8.15.3 Relay Therapeutics AI In Drug Development Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Relay Therapeutics AI In Drug Development Product Portfolio
  90. 8.15.5 Relay Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst